{
    "organizations": [],
    "uuid": "6af6f9ca0d0a91b72beb846620fa5eac9a9c1115",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-promis-neurosciences-lead-product/brief-promis-neurosciences-lead-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1QO0D9",
    "ord_in_thread": 0,
    "title": "BRIEF-ProMIS Neurosciences Lead Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - ProMIS Neurosciences Inc:\n* PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMERâ€™S DISEASE SHOWS POTENTIAL FOR IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES\n* PROMIS NEUROSCIENCES INC - PMN310 SHOWED SIMILAR ABILITY TO CROSS BLOOD BRAIN BARRIER AND PENETRATE CENTRAL NERVOUS SYSTEM COMPARED TO ADUCANUMAB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T20:43:00.000+02:00",
    "crawled": "2018-03-07T19:46:32.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "promis",
        "neuroscience",
        "inc",
        "promis",
        "neuroscience",
        "lead",
        "product",
        "candidate",
        "alzheimer",
        "disease",
        "show",
        "potential",
        "improved",
        "therapeutic",
        "potency",
        "versus",
        "amyloid",
        "antibody",
        "promis",
        "neuroscience",
        "inc",
        "pmn310",
        "showed",
        "similar",
        "ability",
        "cross",
        "blood",
        "brain",
        "barrier",
        "penetrate",
        "central",
        "nervous",
        "system",
        "compared",
        "aducanumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}